Literature DB >> 8314300

Patterns of allele losses suggest the existence of five distinct regions of LOH on chromosome 17 in breast cancer.

R Kirchweger1, R Zeillinger, C Schneeberger, P Speiser, G Louason, C Theillet.   

Abstract

Chromosome 17 is a frequent target during breast-cancer formation and progression. It has been shown to be affected by allele losses at multiple sites, as well as by DNA amplification. Our aim was to delineate a map of the genetic alterations on chromosome 17 in a given set of breast tumors. To this end we analyzed 151 pairs of tumor and cognate lymphocyte DNAs by Southern blotting with 5 RFLP or VNTR probes and by PCR at 8 CA repeat polymorphic loci for LOHs. Moreover, we studied DNA amplification of the evi2, erbB2, thraI, gcsf and rara genes. Data presented here point strongly to the existence of 5 distinct regions of allele losses on chromosome 17:2 on 17p, 3 on 17q. Of the 2 regions on 17p, one involves tp53 while the second is located more distally toward the telomere. LOH was found in 45.9% and 58.8% respectively. The 3 regions on 17q are located: (i) on the proximal portion of the long arm band q21, corresponding to the brcaI region; (ii) in a central region defined by the marker D17S74; (iii) on the distal part of 17q (band q25) characterized by losses of the marker D17S24. Each of these regions presented respectively allele losses in 47.5%, 33.3% and 40.8% of the informative tumors. Whereas some tumors presented patterns of LOH consistent with the loss of a complete chromosomal arm or of large portions of the chromosome, a high proportion of the analyzed tumors showed interstitial losses. Amplifications were found in 15% of the tumors and were centered around erbB2.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8314300     DOI: 10.1002/ijc.2910560208

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

1.  Multiplex genotype analysis of invasive carcinoma and accompanying proliferative lesions microdissected from breast tissue.

Authors:  X Cui; H Feiner; Z Lin; H Li
Journal:  J Mol Diagn       Date:  2000-02       Impact factor: 5.568

2.  Analysis of BRCA1 involvement in breast cancer in Indian women.

Authors:  P H Pestonjamasp; I Mittra
Journal:  J Biosci       Date:  2000-03       Impact factor: 1.826

Review 3.  Molecular genetics of familial breast-ovarian cancer.

Authors:  E J van Rensburg; B A Ponder
Journal:  J Clin Pathol       Date:  1995-09       Impact factor: 3.411

4.  Allelic Losses from Chromosome 17 in Human Osteosarcomas.

Authors:  Marianna Sztán; Zsuzsa Pápai; Miklós Szendrôi; Marco van der Looij; Edith Oláh
Journal:  Pathol Oncol Res       Date:  1997       Impact factor: 3.201

5.  Prognostic value of genomic alterations in minimal residual cancer cells purified from the blood of breast cancer patients.

Authors:  F Austrup; P Uciechowski; C Eder; B Böckmann; B Suchy; G Driesel; S Jäckel; I Kusiak; H J Grill; M Giesing
Journal:  Br J Cancer       Date:  2000-12       Impact factor: 7.640

6.  Genomic instability at the 13q31 locus and somatic mtDNA mutation in the D-loop site correlate with tumor aggressiveness in sporadic Brazilian breast cancer cases.

Authors:  Gilson Costa dos Santos; Andréa Carla de Souza Góes; Humberto de Vitto; Carla Cristina Moreira; Elizabeth Avvad; Franklin David Rumjanek; Claudia Vitoria de Moura Gallo
Journal:  Clinics (Sao Paulo)       Date:  2012-10       Impact factor: 2.365

7.  Clinical impact of detection of loss of heterozygosity of BRCA1 and BRCA2 markers in sporadic breast cancer.

Authors:  M W Beckmann; F Picard; H X An; C R van Roeyen; S I Dominik; D S Mosny; H G Schnürch; H G Bender; D Niederacher
Journal:  Br J Cancer       Date:  1996-05       Impact factor: 7.640

8.  Interphase cytogenetics reveals a high incidence of aneuploidy and intra-tumour heterogeneity in breast cancer.

Authors:  M Fiegl; C Tueni; T Schenk; R Jakesz; M Gnant; A Reiner; M Rudas; H Pirc-Danoewinata; C Marosi; H Huber
Journal:  Br J Cancer       Date:  1995-07       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.